Navigation Links
VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year'


BEDFORD, Mass., Dec. 1 /PRNewswire/ -- The Radiologic Society of North America (RSNA) honored Ralph Weissleder, MD, PhD, with its "Outstanding Researcher of The Year" Award, recognition afforded annually to one scientist who has made original significant contributions to the field of radiology throughout a career of research. Dr. Weissleder is Professor at Harvard Medical School, as well as Director of both the Center for Systems Biology and the Center for Molecular Imaging Research at Massachusetts General Hospital (MGH).

"The RSNA 'Outstanding Researcher of the Year' award is an important acknowledgement of Dr. Weissleder's vision for molecular imaging as an integral component in the future of clinical medicine," said Kirtland Poss, CEO of VisEn Medical. "Dr. Weissleder's contributions have already benefited basic research and pharmaceutical development across numerous disease states, and these are increasingly advancing the era of personalized- and improved-medicine."

According to the RSNA, each "Outstanding Researcher of the Year" honoree has demonstrated a long-term commitment to radiologic research, including service as a principal investigator on peer-reviewed, nationally funded research programs, mentoring a new generation of research physicians, and leading significant scientific discoveries.

Dr. Weissleder has published over 500 peer-reviewed articles and is a founding member and past President of the Society for Molecular Imaging Research. He is the recipient of numerous scientific awards including the Allyn Taylor Prize in International Medicine, an SMI Lifetime Achievement Award and the Millennium Innovator in Medicine award.

Dr. Weissleder is also known for his significant contributions to molecular imaging research. Most of his work has been aimed at cancer, atherosclerosis and inflammatory diseases and has led to new approaches in the management of these diseases.

Dr. Weissleder is a co-founder of VisEn Medical, which has further developed and commercialized some of the leading fluorescence molecular imaging technologies originating out of Dr. Weissleder's lab at MGH, including "FMT" or fluorescent molecular tomography, as well as a portfolio of fluorescence in vivo imaging agents. The VisEn FMT 2500(TM) quantitative tomography system provides 3D quantification of disease biologies in vivo and is used by leading research institutions and pharma companies worldwide both in research and in drug development. In addition, VisEn develops and markets a broad range of fluorescent in vivo imaging agents enabling the quantification and measurement of key disease-associated biomarkers and therapeutic responses in vivo. These agents are used preclinically today, and along with the Fox Chase Cancer Center, VisEn's first "smart" fluorescence activatable agent is being planned for clinical trials in late 2009 to enable physicians to identify and characterize early stage disease in pancreatic and ovarian cancer patients.

Information on Dr. Weissleder and his work at the MGH can be found on: and

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMT) Imaging Systems provide the industry's most robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific preclinical and clinical research areas.

Additional information can be found at

SOURCE VisEn Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
2. VisEn Medical Raises $5.0 Million in Expanded Series B Financing
3. GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow
4. Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation
5. Statement by Steve Case, Co-Founder, AOL and Chairman of Accelerate Brain Cancer Cure ( on News of Senator Ted Kennedys Brain Cancer Diagnosis
6. The Chopra Center Co-founders Bring Mind-Body Healing to New York City
7. The Chopra Center Co-founders Will Teach a Beginning Course in Meditation and Mind-body Healing This August in Chicago
8. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
9. Allscripts Named to FORTUNE 100 Fastest-Growing Companies List
10. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
11. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
Post Your Comments:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched ... be a convenient and comfortable way to protect them from bad weather, so I ... travel during cold or inclement weather. In doing so, it ensures that the user ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
(Date:11/24/2015)... Mississauga, ON (PRWEB) , ... November 24, 2015 , ... ... Deborah Williams without a referral for dental implants at her Mississauga, ON ... qualified and experienced in the placement of dental implants. , Missing teeth can ...
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced that ... Clinical Trial Supply East Asia Conference, to be held at the InterContinental Seoul ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 Endo International plc (NASDAQ: ENDP ... , President and CEO, will discuss corporate updates at the ... New York on Wednesday, December 2, 2015 ... on Investor Relations, and then the link to the event. ... start time to visit the site and download any streaming ...
(Date:11/25/2015)... 2015 Asia -based ... BioLight and the New Investors will make a direct ... a private placement. The financing will help IOPtima to ... used in the treatment of glaucoma, as well as ... IOPtimate™ system with the U.S. Food and Drug Administration, ...
(Date:11/25/2015)... 2015 - Will Also Offer ... (CME) --> - Will Also ... (CME) --> - Will ... Medical Education (CME) Elsevier , a ... will feature latest diagnostic imaging textbooks and decision support tools, as ...
Breaking Medicine Technology: